Trends in the susceptibility of clinically important resistant bacteria to tigecycline: Results from the tigecycline In Vitro surveillance in Taiwan study, 2006 to 2010

Yen Hsu Chen, Po Liang Lu, Cheng Hua Huang, Chun Hsing Liao, Chin Te Lu, Yin Ching Chuang, Shih Ming Tsao, Yao Shen Chen, Yung Ching Liu, Wei Yu Chen, Tsrang Neng Jang, Hsiu Chen Lin, Chih Ming Chen, Zhi Yuan Shi, Sung Ching Pan, Jia Ling Yang, Hsiang Chi Kung, Chun Eng Liu, Yu Jen Cheng, Jien Wei LiuWu Sun, Lih Shinn Wang, Wen Chien Ko, Kwok Woon Yu, Ping Cherng Chiang, Ming Hsun Lee, Chun Ming Lee, Gwo Jong Hsu, Po Ren Hsueh

研究成果: 雜誌貢獻文章

32 引文 (Scopus)

摘要

The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, a nationwide, prospective surveillance during 2006 to 2010, collected a total of 7,793 clinical isolates, including methicillin-resistant Staphylococcus aureus (MRSA) (n = 1,834), penicillin-resistant Streptococcus pneumoniae (PRSP) (n = 423), vancomycin-resistant enterococci (VRE) (n = 219), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (n = 1,141), ESBL-producing Klebsiella pneumoniae (n = 1,330), Acinetobacter baumannii (n = 1,645), and Stenotrophomonas maltophilia (n = 903), from different specimens from 20 different hospitals in Taiwan. MICs of tigecycline were determined following the criteria of the U.S. Food and Drug Administration (FDA) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST-2011). Among drug-resistant Gram-positive pathogens, all of the PRSP isolates were susceptible to tigecycline (MIC 90, 0.03 μg/ml), and only one MRSA isolate (MIC 90, 0.5 μg/ml) and three VRE isolates (MIC 90, 0.125 μg/ml) were nonsusceptible to tigecycline. Among the Gram-negative bacteria, the tigecycline susceptibility rates were 99.65% for ESBL-producing E. coli (MIC 90, 0.5 μg/ml) and 96.32% for ESBL-producing K. pneumoniae (MIC 90, 2 μg/ml) when interpreted by FDA criteria but were 98.7% and 85.8%, respectively, when interpreted by EUCAST-2011 criteria. The susceptibility rate for A. baumannii (MIC 90, 4 μg/ml) decreased from 80.9% in 2006 to 55.3% in 2009 but increased to 73.4% in 2010. A bimodal MIC distribution was found among carbapenem-susceptible A. baumannii isolates, and a unimodal MIC distribution was found among carbapenem-nonsusceptible A. baumannii isolates. In Taiwan, tigecycline continues to have excellent in vitro activity against several major clinically important drug-resistant bacteria, with the exception of A. baumannii.

原文英語
頁(從 - 到)1452-1457
頁數6
期刊Antimicrobial Agents and Chemotherapy
56
發行號3
DOIs
出版狀態已發佈 - 三月 2012

指紋

Acinetobacter baumannii
Taiwan
Bacteria
Carbapenems
Klebsiella pneumoniae
United States Food and Drug Administration
Methicillin-Resistant Staphylococcus aureus
Streptococcus pneumoniae
Penicillins
Escherichia coli
Stenotrophomonas maltophilia
Gram-Negative Bacteria
Pharmaceutical Preparations
tigecycline
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

引用此文

Trends in the susceptibility of clinically important resistant bacteria to tigecycline : Results from the tigecycline In Vitro surveillance in Taiwan study, 2006 to 2010. / Chen, Yen Hsu; Lu, Po Liang; Huang, Cheng Hua; Liao, Chun Hsing; Lu, Chin Te; Chuang, Yin Ching; Tsao, Shih Ming; Chen, Yao Shen; Liu, Yung Ching; Chen, Wei Yu; Jang, Tsrang Neng; Lin, Hsiu Chen; Chen, Chih Ming; Shi, Zhi Yuan; Pan, Sung Ching; Yang, Jia Ling; Kung, Hsiang Chi; Liu, Chun Eng; Cheng, Yu Jen; Liu, Jien Wei; Sun, Wu; Wang, Lih Shinn; Ko, Wen Chien; Yu, Kwok Woon; Chiang, Ping Cherng; Lee, Ming Hsun; Lee, Chun Ming; Hsu, Gwo Jong; Hsueh, Po Ren.

於: Antimicrobial Agents and Chemotherapy, 卷 56, 編號 3, 03.2012, p. 1452-1457.

研究成果: 雜誌貢獻文章

Chen, YH, Lu, PL, Huang, CH, Liao, CH, Lu, CT, Chuang, YC, Tsao, SM, Chen, YS, Liu, YC, Chen, WY, Jang, TN, Lin, HC, Chen, CM, Shi, ZY, Pan, SC, Yang, JL, Kung, HC, Liu, CE, Cheng, YJ, Liu, JW, Sun, W, Wang, LS, Ko, WC, Yu, KW, Chiang, PC, Lee, MH, Lee, CM, Hsu, GJ & Hsueh, PR 2012, 'Trends in the susceptibility of clinically important resistant bacteria to tigecycline: Results from the tigecycline In Vitro surveillance in Taiwan study, 2006 to 2010', Antimicrobial Agents and Chemotherapy, 卷 56, 編號 3, 頁 1452-1457. https://doi.org/10.1128/AAC.06053-11
Chen, Yen Hsu ; Lu, Po Liang ; Huang, Cheng Hua ; Liao, Chun Hsing ; Lu, Chin Te ; Chuang, Yin Ching ; Tsao, Shih Ming ; Chen, Yao Shen ; Liu, Yung Ching ; Chen, Wei Yu ; Jang, Tsrang Neng ; Lin, Hsiu Chen ; Chen, Chih Ming ; Shi, Zhi Yuan ; Pan, Sung Ching ; Yang, Jia Ling ; Kung, Hsiang Chi ; Liu, Chun Eng ; Cheng, Yu Jen ; Liu, Jien Wei ; Sun, Wu ; Wang, Lih Shinn ; Ko, Wen Chien ; Yu, Kwok Woon ; Chiang, Ping Cherng ; Lee, Ming Hsun ; Lee, Chun Ming ; Hsu, Gwo Jong ; Hsueh, Po Ren. / Trends in the susceptibility of clinically important resistant bacteria to tigecycline : Results from the tigecycline In Vitro surveillance in Taiwan study, 2006 to 2010. 於: Antimicrobial Agents and Chemotherapy. 2012 ; 卷 56, 編號 3. 頁 1452-1457.
@article{5475ea3ea75e436fa6fc46b54fd96658,
title = "Trends in the susceptibility of clinically important resistant bacteria to tigecycline: Results from the tigecycline In Vitro surveillance in Taiwan study, 2006 to 2010",
abstract = "The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, a nationwide, prospective surveillance during 2006 to 2010, collected a total of 7,793 clinical isolates, including methicillin-resistant Staphylococcus aureus (MRSA) (n = 1,834), penicillin-resistant Streptococcus pneumoniae (PRSP) (n = 423), vancomycin-resistant enterococci (VRE) (n = 219), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (n = 1,141), ESBL-producing Klebsiella pneumoniae (n = 1,330), Acinetobacter baumannii (n = 1,645), and Stenotrophomonas maltophilia (n = 903), from different specimens from 20 different hospitals in Taiwan. MICs of tigecycline were determined following the criteria of the U.S. Food and Drug Administration (FDA) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST-2011). Among drug-resistant Gram-positive pathogens, all of the PRSP isolates were susceptible to tigecycline (MIC 90, 0.03 μg/ml), and only one MRSA isolate (MIC 90, 0.5 μg/ml) and three VRE isolates (MIC 90, 0.125 μg/ml) were nonsusceptible to tigecycline. Among the Gram-negative bacteria, the tigecycline susceptibility rates were 99.65{\%} for ESBL-producing E. coli (MIC 90, 0.5 μg/ml) and 96.32{\%} for ESBL-producing K. pneumoniae (MIC 90, 2 μg/ml) when interpreted by FDA criteria but were 98.7{\%} and 85.8{\%}, respectively, when interpreted by EUCAST-2011 criteria. The susceptibility rate for A. baumannii (MIC 90, 4 μg/ml) decreased from 80.9{\%} in 2006 to 55.3{\%} in 2009 but increased to 73.4{\%} in 2010. A bimodal MIC distribution was found among carbapenem-susceptible A. baumannii isolates, and a unimodal MIC distribution was found among carbapenem-nonsusceptible A. baumannii isolates. In Taiwan, tigecycline continues to have excellent in vitro activity against several major clinically important drug-resistant bacteria, with the exception of A. baumannii.",
author = "Chen, {Yen Hsu} and Lu, {Po Liang} and Huang, {Cheng Hua} and Liao, {Chun Hsing} and Lu, {Chin Te} and Chuang, {Yin Ching} and Tsao, {Shih Ming} and Chen, {Yao Shen} and Liu, {Yung Ching} and Chen, {Wei Yu} and Jang, {Tsrang Neng} and Lin, {Hsiu Chen} and Chen, {Chih Ming} and Shi, {Zhi Yuan} and Pan, {Sung Ching} and Yang, {Jia Ling} and Kung, {Hsiang Chi} and Liu, {Chun Eng} and Cheng, {Yu Jen} and Liu, {Jien Wei} and Wu Sun and Wang, {Lih Shinn} and Ko, {Wen Chien} and Yu, {Kwok Woon} and Chiang, {Ping Cherng} and Lee, {Ming Hsun} and Lee, {Chun Ming} and Hsu, {Gwo Jong} and Hsueh, {Po Ren}",
year = "2012",
month = "3",
doi = "10.1128/AAC.06053-11",
language = "English",
volume = "56",
pages = "1452--1457",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Trends in the susceptibility of clinically important resistant bacteria to tigecycline

T2 - Results from the tigecycline In Vitro surveillance in Taiwan study, 2006 to 2010

AU - Chen, Yen Hsu

AU - Lu, Po Liang

AU - Huang, Cheng Hua

AU - Liao, Chun Hsing

AU - Lu, Chin Te

AU - Chuang, Yin Ching

AU - Tsao, Shih Ming

AU - Chen, Yao Shen

AU - Liu, Yung Ching

AU - Chen, Wei Yu

AU - Jang, Tsrang Neng

AU - Lin, Hsiu Chen

AU - Chen, Chih Ming

AU - Shi, Zhi Yuan

AU - Pan, Sung Ching

AU - Yang, Jia Ling

AU - Kung, Hsiang Chi

AU - Liu, Chun Eng

AU - Cheng, Yu Jen

AU - Liu, Jien Wei

AU - Sun, Wu

AU - Wang, Lih Shinn

AU - Ko, Wen Chien

AU - Yu, Kwok Woon

AU - Chiang, Ping Cherng

AU - Lee, Ming Hsun

AU - Lee, Chun Ming

AU - Hsu, Gwo Jong

AU - Hsueh, Po Ren

PY - 2012/3

Y1 - 2012/3

N2 - The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, a nationwide, prospective surveillance during 2006 to 2010, collected a total of 7,793 clinical isolates, including methicillin-resistant Staphylococcus aureus (MRSA) (n = 1,834), penicillin-resistant Streptococcus pneumoniae (PRSP) (n = 423), vancomycin-resistant enterococci (VRE) (n = 219), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (n = 1,141), ESBL-producing Klebsiella pneumoniae (n = 1,330), Acinetobacter baumannii (n = 1,645), and Stenotrophomonas maltophilia (n = 903), from different specimens from 20 different hospitals in Taiwan. MICs of tigecycline were determined following the criteria of the U.S. Food and Drug Administration (FDA) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST-2011). Among drug-resistant Gram-positive pathogens, all of the PRSP isolates were susceptible to tigecycline (MIC 90, 0.03 μg/ml), and only one MRSA isolate (MIC 90, 0.5 μg/ml) and three VRE isolates (MIC 90, 0.125 μg/ml) were nonsusceptible to tigecycline. Among the Gram-negative bacteria, the tigecycline susceptibility rates were 99.65% for ESBL-producing E. coli (MIC 90, 0.5 μg/ml) and 96.32% for ESBL-producing K. pneumoniae (MIC 90, 2 μg/ml) when interpreted by FDA criteria but were 98.7% and 85.8%, respectively, when interpreted by EUCAST-2011 criteria. The susceptibility rate for A. baumannii (MIC 90, 4 μg/ml) decreased from 80.9% in 2006 to 55.3% in 2009 but increased to 73.4% in 2010. A bimodal MIC distribution was found among carbapenem-susceptible A. baumannii isolates, and a unimodal MIC distribution was found among carbapenem-nonsusceptible A. baumannii isolates. In Taiwan, tigecycline continues to have excellent in vitro activity against several major clinically important drug-resistant bacteria, with the exception of A. baumannii.

AB - The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, a nationwide, prospective surveillance during 2006 to 2010, collected a total of 7,793 clinical isolates, including methicillin-resistant Staphylococcus aureus (MRSA) (n = 1,834), penicillin-resistant Streptococcus pneumoniae (PRSP) (n = 423), vancomycin-resistant enterococci (VRE) (n = 219), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (n = 1,141), ESBL-producing Klebsiella pneumoniae (n = 1,330), Acinetobacter baumannii (n = 1,645), and Stenotrophomonas maltophilia (n = 903), from different specimens from 20 different hospitals in Taiwan. MICs of tigecycline were determined following the criteria of the U.S. Food and Drug Administration (FDA) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST-2011). Among drug-resistant Gram-positive pathogens, all of the PRSP isolates were susceptible to tigecycline (MIC 90, 0.03 μg/ml), and only one MRSA isolate (MIC 90, 0.5 μg/ml) and three VRE isolates (MIC 90, 0.125 μg/ml) were nonsusceptible to tigecycline. Among the Gram-negative bacteria, the tigecycline susceptibility rates were 99.65% for ESBL-producing E. coli (MIC 90, 0.5 μg/ml) and 96.32% for ESBL-producing K. pneumoniae (MIC 90, 2 μg/ml) when interpreted by FDA criteria but were 98.7% and 85.8%, respectively, when interpreted by EUCAST-2011 criteria. The susceptibility rate for A. baumannii (MIC 90, 4 μg/ml) decreased from 80.9% in 2006 to 55.3% in 2009 but increased to 73.4% in 2010. A bimodal MIC distribution was found among carbapenem-susceptible A. baumannii isolates, and a unimodal MIC distribution was found among carbapenem-nonsusceptible A. baumannii isolates. In Taiwan, tigecycline continues to have excellent in vitro activity against several major clinically important drug-resistant bacteria, with the exception of A. baumannii.

UR - http://www.scopus.com/inward/record.url?scp=84863116394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863116394&partnerID=8YFLogxK

U2 - 10.1128/AAC.06053-11

DO - 10.1128/AAC.06053-11

M3 - Article

C2 - 22203598

AN - SCOPUS:84863116394

VL - 56

SP - 1452

EP - 1457

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 3

ER -